Skip to main content
All insights
Capital Markets & M&A

Schneider’s $23.7 Billion PTC Deal Needs More Than Cost Savings

Schneider Electric is paying a 42.3% premium for PTC and funding most of the purchase with debt. The advertised valuation falls from 21 times to 13 times 2027 adjusted EBITA only after a demanding combination of cost savings and commercial synergies.

Alliance Equity Research6 min read
Precision industrial machinery overlaid with a digital wireframe model inside an automated factory.

A premium price for industrial software

Schneider Electric has agreed to acquire PTC for $205 per share in cash, valuing the target’s equity at approximately $22.6 billion and its enterprise value at $23.7 billion. The October 5 agreement carries a 42.3% premium to PTC’s previous close and a 46.1% premium to its 30-trading-day volume-weighted average price.

The market’s initial response separated the two sides of the transaction. PTC shares moved toward the offer price, while Schneider shares fell nearly 10% in early Paris trading on October 5, erasing close to €15 billion of market value. That reaction can change, but it shows where investors placed the near-term burden of proof.

PTC brings computer-aided design, product lifecycle management, application lifecycle management and service lifecycle management software used by more than 30,000 customers. Schneider gains the product-design and engineering layer that precedes the factory automation and energy-management systems it already supplies.

The 13-times multiple depends on the full synergy plan

Schneider presents two acquisition multiples: 21 times estimated 2027 adjusted EBITA before synergies and 13 times after full run-rate synergies. The €21.1 billion enterprise value therefore implies about €1.00 billion of standalone 2027 adjusted EBITA and roughly €1.62 billion after synergies.

The difference is approximately €618 million. Schneider has identified €250 million of annual cost synergies by the third year and about €800 million of revenue synergies. After deducting the cost savings, the multiple arithmetic implies approximately €368 million of adjusted EBITA from the additional revenue, equivalent to a 46% margin on the €800 million sales target.

Valuation bridgeImplied amount
Enterprise value€21.1 billion
Standalone 2027 adjusted EBITA at 21×Approximately €1.00 billion
Adjusted EBITA including full synergies at 13×Approximately €1.62 billion
Implied total EBITA upliftApproximately €618 million
Announced annual cost synergies€250 million
Implied EBITA from €800 million revenue synergiesApproximately €368 million
Implied margin on revenue synergiesApproximately 46%

The figures are derived from rounded transaction multiples, so they are estimates. They clarify the assumptions embedded in the 13-times figure: cost savings account for about 40% of the implied EBITA uplift, leaving most of the remaining contribution to cross-selling and joint product development.

That commercial target is large beside PTC’s current base. The transaction materials cite approximately €2.4 billion of calendar 2025 revenue, excluding revenue from the divested ThingWorx and Kepware businesses. An additional €800 million would equal one-third of that base. Realization is likely to require several years of channel expansion, customer conversion and product integration.

PTC offers growth, margins and cash conversion

PTC’s financial profile explains the strategic appeal. The deal materials describe calendar 2025 adjusted EBITA margins of approximately 40% and expect annual recurring revenue and revenue to grow at around 10% from 2026 through 2029, based on broker consensus.

Its third-quarter fiscal 2026 results reported $2.41 billion of annual recurring revenue excluding divested businesses, up 7% as reported and 9.1% at constant currency. Quarterly free cash flow was $249 million, and full-year guidance remained approximately $850 million.

Revenue comparisons require care because PTC’s subscription accounting under ASC 606 creates timing differences, while the March divestiture removed Kepware and ThingWorx from the continuing base. Third-quarter reported revenue fell 7% to $600 million even as constant-currency recurring revenue grew. ARR and cash generation provide cleaner indicators of the business Schneider is buying.

At $23.7 billion, the transaction enterprise value equals approximately 27.9 times PTC’s $850 million fiscal 2026 free-cash-flow guidance. That guidance includes several divestiture-related inflows, costs and taxes that are not expected to recur, so the simple multiple is a scale reference and not a normalized valuation.

Debt carries most of the funding load

Schneider has secured a fully committed bridge facility for approximately €22 billion of cash consideration. The permanent funding plan combines €5 billion to €6 billion of new equity with €16 billion to €17 billion of new debt.

Funding sourcePlanned amountShare of €22 billion consideration
New equity€5 billion to €6 billionApproximately 23% to 27%
New debt€16 billion to €17 billionApproximately 73% to 77%

The exact dilution will depend on the equity issuance price and final amount. Debt supplies roughly three-quarters of the purchase consideration, increasing the importance of PTC’s cash conversion and timely synergy delivery.

The scale is visible against Schneider’s existing earnings. First-half 2026 results included €4.1 billion of adjusted EBITA and €1.6 billion of free cash flow. The planned new debt is about four times that six-month adjusted EBITA and ten times the six-month free cash flow figure. These comparisons do not represent pro forma leverage ratios because they mix incremental gross debt with half-year operating measures and exclude PTC, the equity financing, transaction cash flows and subsequent earnings.

Management expects the combined business to be accretive to adjusted earnings per share before purchase-price accounting in the first full year of consolidation. Accretion is projected in the low single digits before synergies and the mid-to-high single digits with full run-rate synergies. Schneider also expects transaction return on capital employed to exceed its weighted average cost of capital by the fifth year after closing.

Strategic fit reaches from design to operations

Schneider’s industrial software portfolio is centered on AVEVA, process and energy data, automation and asset operations. Its proposed Cognite acquisition adds industrial data and AI capabilities. PTC adds product and engineering data generated before an asset reaches the factory floor or enters service.

Combining those layers could create a digital thread spanning design, manufacturing, operation and maintenance. Schneider estimates that PTC expands its addressable industrial-software market by roughly three times and gives the group more exposure to discrete and hybrid manufacturing.

The strategic logic relies on interoperability and customer adoption. Industrial customers use mixed software estates, long product cycles and deeply embedded workflows. Preserving open connections while combining data models, sales channels and product road maps will determine whether the platform produces incremental sales or adds another integration layer.

What to watch before the 2027 closing

The transaction is expected to close by the third quarter of 2027, subject to approval from holders of a majority of PTC’s outstanding shares and required regulatory clearances. The cash premium supports the shareholder vote, while the size of the combination and the importance of industrial data make regulatory review a relevant part of the timetable.

Three disclosures will help investors assess progress. First, the terms and pricing of the €5 billion to €6 billion equity issue will establish actual dilution. Second, the maturity and interest cost of the €16 billion to €17 billion debt package will define the financing burden. Third, Schneider needs to separate cost savings from signed customer wins so the €800 million revenue-synergy target can be measured.

PTC gives Schneider a high-margin software asset with recurring revenue, cash generation and a strategic position in product engineering data. The acquisition price already capitalizes much of that quality. Reaching the advertised 13-times multiple requires Schneider to deliver the cost program and convert a cross-selling target equal to roughly one-third of PTC’s 2025 revenue into high-margin sales.

This material is provided for informational and educational purposes only and does not constitute investment advice or a recommendation to buy or sell any security.

About AER Insights

Alliance Equity Research publishes timely insights on company-specific developments, industry trends, capital markets activity, and emerging investment themes across global public markets, with a particular focus on undercovered companies, sectors, and developments that often receive limited attention from mainstream financial research. Our analysis focuses on the financial, strategic, and valuation implications behind the headlines, using company disclosures, filings, market data, and sector context to help investors understand what matters, why it matters, and what to watch next.

Get AER Insights by Email

Receive new AER Insights and research updates in your inbox.

Subscribe
Unlabelled glass pharmaceutical vials on a laboratory bench, with analytical equipment in the background.Biotechnology & Healthcare

Vaxcyte’s Phase 3 Success Advances a Broader Vaccine Toward Its Next Regulatory Tests

VAX-31 passed every primary endpoint in its pivotal adult trial, supporting a broader pneumococcal vaccine profile. Individual comparator results, remaining manufacturing studies and rising development spending will shape the path to Vaxcyte’s planned 2028 filing and eventual commercial opportunity.

Alliance Equity ResearchOctober 5, 20265 min read
Read article
White tablets beside an unlabelled glass jar on a laboratory bench, with a microscope and glassware in the background.Biotechnology & Healthcare

Jaypirca Moves Into First-Line CLL, Expanding Lilly’s Oncology Opportunity in a Crowded Market

FDA approval brings Lilly’s noncovalent BTK inhibitor into initial treatment for eligible patients with chronic lymphocytic leukemia. The commercial opportunity now extends earlier in the disease course, while competing targeted therapies, treatment duration and tolerability will determine how much of that opportunity becomes revenue.

Alliance Equity ResearchOctober 4, 20265 min read
Read article
A reel of steel rod and cylindrical pump components in an industrial workshop, with an oil pumping unit visible outside.Capital Markets & M&A

Flowco’s $113 Million Deal Expands Its Role in Keeping Older Wells Productive

Flowco’s acquisition of Lifting Solutions adds continuous rod and progressing cavity pumps to its artificial lift portfolio. The purchase extends its Canadian and international reach, with returns dependent on equipment performance, cross-selling and cash generation as the group absorbs a second acquisition this year.

Alliance Equity ResearchOctober 4, 20265 min read
Read article
An iridescent silicon wafer rests on processing equipment in a bright industrial cleanroom, with stainless steel machinery and a distant technician.Technology & Semiconductors

Micron’s Customers Are Helping Fund Its Next Expansion as Memory Demand Surges

Customer deposits exceeded Micron’s quarterly net capital expenditure as revenue and operating cash flow reached new highs. Combined with longer-term purchase agreements, that funding gives Micron greater capacity to expand supply, while shifting the investment debate toward contract profitability and returns on new factories.

Alliance Equity ResearchOctober 4, 20265 min read
Read article
View all insights